Ocular Therapeutix
OCUL
141 hedge funds and large institutions have $445M invested in Ocular Therapeutix in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 48 reducing their positions, and 23 closing their positions.
99% more call options, than puts
Call options by funds: $19M | Put options by funds: $9.56M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
2% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 48
5.24% less ownership
Funds ownership: 63.4% → 58.16% (-5.2%)
5% less funds holding
Funds holding: 149 → 141 (-8)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
35% less capital invested
Capital invested by funds: $685M → $445M (-$239M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$5.62M |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$4.85M |
| 3 |
ACM
Altium Capital Management
New York
|
+$3.37M |
| 4 |
Millennium Management
New York
|
+$2.99M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$20.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$10.6M |
| 4 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$4.84M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$4.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAS
151
TIFF Advisory Services
Radnor,
Pennsylvania
| – | -$276K | -14,224 | Closed |
|
|
EGM
152
Engineers Gate Manager
New York
| – | -$196K | -13,816 | Closed |
|
|
TC
153
TwinBeech Capital
Purchase,
New York
| – | -$189K | -13,311 | Closed |
|
|
VF
154
Virtu Financial
New York
| – | -$179K | -12,641 | Closed |
|
155
Ameriprise
Minneapolis,
Minnesota
| – | -$162K | -11,413 | Closed |
|
156
Walleye Trading
New York
| – | -$80K | -5,657 | Closed |
|
|
QT
157
Quantbot Technologies
New York
| – | -$44K | -3,151 | Closed |
|
|
LSA
158
Leonteq Securities AG
Zurich,
Switzerland
| – | -$28.4K | -2,000 | Closed |
|
|
ED
159
Exane Derivatives
Paris,
France
| – | -$19.3K | -1,496 | Closed |
|
|
PAM
160
Panagora Asset Management
Boston,
Massachusetts
| – | -$20K | -1,378 | Closed |
|
|
PHK
161
Point72 Hong Kong
Hong Kong
| – | -$19K | -1,326 | Closed |
|
|
HNB
162
Huntington National Bank
Columbus,
Ohio
| – | -$6K | -400 | Closed |
|
|
ASN
163
Advisory Services Network
Atlanta,
Georgia
| – | -$4K | -250 | Closed |
|
OCUL Hedge Fund Activity: Q3 2021 in Review
141 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2021, worth a combined $445M — down 35% from $685M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of OCUL and 16 opened new positions — a net loss of 7 holders — while 48 trimmed existing stakes and 49 added.
The largest buyer was Affinity Asset Advisors, adding an estimated $5.62M. The largest seller was Rubric Capital Management (New York), cutting an estimated $20.2M.
- 141 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2021, down from 149 in Q2 2021.
- Funds reported $445M of Ocular Therapeutix stock for Q3 2021, down 35% quarter-over-quarter.
- 16 funds opened new Ocular Therapeutix positions in Q3 2021 and 23 closed out, a net change of -7 holders.
- The largest Ocular Therapeutix buyer in Q3 2021 was Affinity Asset Advisors, an estimated $5.62M added.
- The largest Ocular Therapeutix seller in Q3 2021 was Rubric Capital Management (New York), an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2021.